Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing...

Area of Science:

• Endocrinology
• Oncology
• Nephrology

Background:

• The Rice-500 Leydig cell tumor (LCT) in Fischer rats serves as a model for humoral hypercalcemia of malignancy (HHM).
• HHM in this model involves elevated plasma calcium (Ca) due to increased bone resorption and enhanced tubular Ca reabsorption (TRCa).

Purpose of the Study:

• To investigate the hypocalcemic effects of WR-2721 in LCT-bearing rats.
• To determine if WR-2721's effect on plasma calcium is mediated by parathyroid hormone (PTH) secretion or by direct effects on TRCa.

Main Methods:

• Administered a single dose of WR-2721 (0.7 mmol/kg body weight) to hypercalcemic LCT-bearing Fischer rats.
• Monitored plasma Ca levels, urinary Ca excretion, and urinary cyclic AMP (cAMP) before and after WR-2721 administration.

Main Results:

• WR-2721 significantly reduced plasma Ca levels within 2 hours post-injection.
• Increased urinary Ca excretion indicated inhibition of TRCa.
• Elevated urinary cAMP levels in LCT-bearing rats remained unchanged after WR-2721 treatment, suggesting a PTH-independent mechanism.

Conclusions:

• WR-2721 normalizes calcemia in this HHM model through a PTH-independent inhibition of TRCa.
• WR-2721 demonstrates potential as a therapeutic agent for human hypercalcemia of malignancy, especially when enhanced renal Ca reabsorption is a contributing factor.